Superseded public profile

FDA-approved↗↗↗↗↗Bone↗

Superseded · version 3: Teriparatide↗

Related names recorded in this version: Forteo↗↗

A parathyroid hormone analogue first approved by FDA as Forteo in 2002 for osteoporosis at high risk of fracture.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked the generic teriparatide label, and added Drugs@FDA approval records for teriparatide products. 12

What this version reported

A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that teriparatide caused osteosarcoma in rats; an increased risk has not been observed in human observational studies.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗

Reader guide in this version

Key takeaway

Teriparatide is a lab-made version of the first 34 amino acids of human parathyroid hormone. It was first approved in the United States as Eli Lilly’s Forteo in 2002.1,2 It is FDA-approved for postmenopausal women with osteoporosis at high risk of fracture, to increase bone mass in men with primary or hypogonadal osteoporosis, and for osteoporosis linked to long-term glucocorticoid use.1 In the label’s main trial of 1,637 postmenopausal women, new spine fractures occurred in 5% of the teriparatide group and 14.3% of the placebo group.1 The label states that teriparatide caused osteosarcoma, a bone cancer, in rats, but that an increased risk has not been observed in observational studies in humans.1

At a glance

What it is
Parathyroid hormone (1-34). The label states that teriparatide binds the same receptors as natural parathyroid hormone, with the same effects on bone and kidney.1
FDA status
FDA-approved. Drugs@FDA lists Forteo with an original approval date of November 26, 2002, and later teriparatide applications. The cited label has no boxed warning.1,2,3,4,5
Human evidence
Large randomized trials described in the label, including a placebo-controlled fracture trial in postmenopausal women.1
Evidence strength
Large randomized human trials

What is teriparatide?

Teriparatide is a lab-made peptide identical to the first 34 amino acids of human parathyroid hormone, the body’s main regulator of calcium and phosphate. The label states that it is made by chemical synthesis.1

Drugs@FDA lists Forteo, from Eli Lilly, approved in 2002, and later teriparatide applications including Bonsity (2019), a generic application approved in 2023 and a further application approved in 2024. The label cited on this page is a generic teriparatide label rather than the Forteo label.1,2,3,4,5

How does teriparatide work?

The label states that teriparatide binds the same receptors as natural parathyroid hormone, with the same affinity and the same effects on bone and kidney.1

The label states that teriparatide stimulates new bone formation by favoring bone-building cells over bone-removing cells.1

What do human studies show?

The label describes a double-blind, placebo-controlled trial in 1,637 postmenopausal women with osteoporosis, most of whom already had a spine fracture. New spine fractures occurred in 5% of the teriparatide group and 14.3% of the placebo group, a relative reduction of 65%.1

In a placebo-controlled trial in 437 men with primary or hypogonadal osteoporosis, spine bone density increased by an average of 5.9% with teriparatide and 0.5% with placebo, according to the label.1

The label also describes an 18-month randomized trial in 428 people with osteoporosis linked to glucocorticoid use.1

What the evidence base contains

  • Controlled human trial A double-blind, placebo-controlled trial in 1,637 postmenopausal women with osteoporosis, with new spine fractures as the main outcome and a median exposure of 19 months.1
  • Controlled human trial A double-blind, placebo-controlled trial in 437 men with primary or hypogonadal osteoporosis that measured spine bone density.1
  • Large randomized human trial An 18-month randomized, double-blind, active-controlled trial in 428 people with osteoporosis linked to glucocorticoid use.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is teriparatide FDA-approved?

Yes. Drugs@FDA lists Forteo, application NDA021318, with an original approval date of November 26, 2002, Bonsity on October 4, 2019, a generic application (ANDA211097) on November 16, 2023 and a further application (NDA218771) on June 4, 2024.2,3,4,5

The generic teriparatide label cited here (DailyMed SPL version 9, published June 30, 2026) states that it is indicated for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and for men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture.1

The label has no boxed warning. It states that teriparatide is contraindicated in people allergic to it or its ingredients, and that allergic reactions have included angioedema and anaphylaxis.1

Its warnings cover a risk of osteosarcoma based on rat studies, high blood calcium and calcium deposits in the skin, kidney stones, a fall in blood pressure on standing, and digoxin toxicity.1

Timeline

  1. FDA approves Forteo, according to Drugs@FDA.2
  2. FDA approves Bonsity, according to Drugs@FDA.3
  3. FDA approves a generic teriparatide application, according to Drugs@FDA.4
  4. DailyMed publishes the teriparatide label version cited on this page.1

What is still unknown?

Whether teriparatide causes osteosarcoma in humans: the label notes cases reported after approval but no increased risk in observational studies, and limited data beyond 2 years.1

Whether it reduces fractures in men: the label’s trial in men measured bone density.1

Sources for this version

  1. 1
    Teriparatide injection, solution · SPL version 9 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA021318 · original submission status AP · 2002-11-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA211939 · original submission status AP · 2019-10-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application ANDA211097 · original submission status AP · 2023-11-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA218771 · original submission status AP · 2024-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026